Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2014 | (b) 2015 | (c) 2016 | (d) 2017 | (e) 2018 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | 240,798,040 | 112,703,072 | 121,777,889 | 113,630,164 | 108,300,329 | 697,209,494 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf.... | 0 | |||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | 0 | |||||
| 4 | Total. Add lines 1 through 3 | 240,798,040 | 112,703,072 | 121,777,889 | 113,630,164 | 108,300,329 | 697,209,494 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f).. | 63,750,592 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 633,458,902 | |||||
Calendar year
(or fiscal year beginning in) ![]() |
(a) 2014 | (b) 2015 | (c) 2016 | (d) 2017 | (e) 2018 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 240,798,040 | 112,703,072 | 121,777,889 | 113,630,164 | 108,300,329 | 697,209,494 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 6,992,391 | 5,532,193 | 6,303,751 | 5,346,565 | 5,942,288 | 30,117,188 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | 0 | 0 | ||||
| 11 | Total support. Add lines 7 through 10 | 727,869,801 | |||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2014 | (b) 2015 | (c) 2016 | (d) 2017 | (e) 2018 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2014 | (b) 2015 | (c) 2016 | (d) 2017 | (e) 2018 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 1-1/2% of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by .035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | ||
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
||
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | ||
| 4 Amounts paid to acquire exempt-use assets | ||
| 5 Qualified set-aside amounts (prior IRS approval required) | ||
| 6 Other distributions (describe in Part VI). See instructions | ||
| 7Total annual distributions. Add lines 1 through 6. | ||
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
||
| 9 Distributable amount for 2018 from Section C, line 6 | ||
| 10 Line 8 amount divided by Line 9 amount | ||
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2018 |
(iii) Distributable Amount for 2018 |
|
|---|---|---|---|---|
|
1
Distributable amount for 2018 from Section C, line 6 |
||||
|
2
Underdistributions, if any, for years prior to 2018 (reasonable cause required-- explain in Part VI). See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2018: | ||||
| a From 2013....... | ||||
| b From 2014....... | ||||
| c From 2015....... | ||||
| d From 2016....... | ||||
| e From 2017....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2018 distributable amount | ||||
|
i
Carryover from 2013 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from 3f. | ||||
| 4Distributions for 2018 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2018 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from 4. | ||||
|
5
Remaining underdistributions for years prior to 2018, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2018. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2019. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2014...... | ||||
| b Excess from 2015..... | ||||
| c Excess from 2016..... | ||||
| d Excess from 2017..... | ||||
| e Excess from 2018..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|
| Software ID: | |
| Software Version: |
Attach to Form 990 or 990-EZ.
Go to www.irs.gov/Form990 for the latest information.
| Return Reference | Explanation |
|---|---|
| FORM 990, PART I, LINE 1 & PART III, LINE 1 | ORGANIZATIONS MISSION SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE CONDUCTS WORLD-CLASS, COLLABORATIVE RESEARCH DEDICATED TO FINDING CURES FOR HUMAN DISEASE, IMPROVING THE QUALITY OF LIFE, AND THUS CREATING A LEGACY FOR ITS EMPLOYEES, PARTNERS, DONORS, AND COMMUNITY. |
| FORM 990, PART III, LINE 4 | PROGRAM SERVICE ACCOMPLISHMENTS SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE (SBP) IS AN INDEPENDENT NONPROFIT MEDICAL RESEARCH ORGANIZATION THAT DEDICATED TO UNCOVERING THE ORIGINS OF DISEASE AND LAUNCHING BOLD NEW STRATEGIES LAYING THE FOUNDATION FOR CURES. OUR INSTITUTE HAS DEEP EXPERTISE IN FUNDAMENTAL BIOLOGY AND ONE OF THE MOST COMPREHENSIVE DRUG DISCOVERY CENTERS IN THE NONPROFIT WORLD. CANCER CONQUERING CANCER'S INFAMOUS KRAS MUTATION. KRAS IS ONE OF THE MOST CHALLENGING TARGETS IN CANCER. DESPITE ITS DISCOVERY MORE THAN 60 YEARS AGO, RESEARCHERS STILL STRUGGLE TO BLOCK THE CANCER-CAUSING PROTEIN - EARNING ITS REPUTATION AS "UNDRUGGABLE." GARTH POWIS, D.PHIL., LED RESEARCH IDENTIFYING A PROMISING COMPOUND CALLED PHT-7.3 THAT SHRINKS KRAS TUMORS IN MICE. NEARLY 25% OF ALL HUMAN CANCERS ARE KRAS-POSITIVE. POTENTIAL TARGETED TREATMENT FOR ACUTE MYELOID LEUKEMIA. ACUTE MYELOID LEUKEMIA IS A DEADLY BLOOD CANCER WITH LIMITED TREATMENT OPTIONS. FOR PATIENTS OVER 20 YEARS OLD, THE 5-YEAR SURVIVAL IS APPROXIMATELY 25%. ANI DESHPANDE, PH.D., FOUND THAT BLOCKING A PROTEIN CALLED BMI1 WITH A SPECIFIC COMPOUND PROLONGED SURVIVAL OF MOUSE MODELS OF THE DISEASE. THE COMPOUND IS IN CLINICAL DEVELOPMENT FOR ADVANCED SOLID TUMORS BY PTC THERAPEUTICS. PANCREATIC TUMORS SCAVENGE TO SURVIVE. RAPIDLY GROWING PANCREATIC TUMORS GATHER NUTRIENTS THROUGH A SUPPLY ROUTE CALLED MICROPINOCYTOSIS, WHEREBY SMALL PARTICLES ARE ENGULFED VIA THE CELL MEMBRANE. COSIMO COMMISSO, PH.D., DISCOVERED THAT SOME TUMORS HAVE NATURALLY HIGH LEVELS OF MICROPINOCYTOSIS, WHILE OTHERS CAN DIAL UP OR DOWN NUTRIENT SCAVENGING AS NEEDED DURING DISEASE PROGRESSION. THE RESEARCH ALSO IDENTIFIED MOLECULAR REGULATORS OF THE PROCESS WHICH MAY ULTIMATELY LEAD TO PERSONALIZED TREATMENTS TO STARVE TUMORS. STUDY OFFERS NEW APPROACH TO STARVING TUMORS. FOR YEARS, SCIENTISTS HAVE TRIED TO HALT CANCER BY BLOCKING THE NUTRIENTS THAT TUMORS NEED TO GROW. THESE STRATEGIES HAVE OFTEN FAILED BECAUSE CANCER CELLS ARE CRAFTY-THEY HAVE BACKUP PLANS TO GATHER THE FOOD AND OXYGEN THAT THEY NEED TO SURVIVE. BROOKE EMERLING, PH.D., LED RESEARCH REVEALING AN ALTERNATIVE METABOLIC PATHWAY USED BY CANCER CELLS THAT MAY BE TARGETED TO STARVE TUMORS. TARGETING LONG-SOUGHT CANCER RECEPTOR BECOMES CRYSTAL CLEAR. SCIENTISTS HAVE LONG SOUGHT TO TARGET A RECEPTOR CALLED EPHA2 BECAUSE OF ITS KNOWN ROLE IN CANCER AND OTHER DISORDERS INCLUDING INFLAMMATORY CONDITIONS, NEUROLOGICAL DISORDERS AND INFECTIOUS DISEASES. ELENA PASQUALE, PH.D., PUBLISHED RESEARCH ON THE STRUCTURE OF THE RECEPTOR AND ENGINEERED POWERFUL COMPOUNDS THAT ACTIVATE OR INACTIVATE IT, PAVING THE WAY FOR NEW THERAPIES. HOW PROSTATE CANCER BECOMES TREATMENT RESISTANT. SOME MEN WHO RECEIVE ANTI-ANDROGEN THERAPY FOR PROSTATE CANCER DEVELOP NEUROENDOCRINE PROSTATE CANCER (NEPC)-A DEADLY SUBTYPE WITH NO EFFECTIVE TREATMENT. MARIA DIAZ-MECO, PH.D., LED A STUDY DESCRIBING THE MOLECULAR "SWITCH" THAT DRIVES THIS TRANSFORMATION. THE FINDINGS REVEAL THAT AN FDA-APPROVED DRUG HOLDS POTENTIAL AS AN NEPC TREATMENT, AND NEW THERAPEUTIC AVENUES THAT COULD PREVENT THE TRANSFORMATION FROM OCCURRING. LOSS OF GENES DRIVES DEADLY COLORECTAL CANCERS. SOME COLON POLYPS PROGRESS TO A TREATMENT-RESISTANT CANCER CALLED SERRATED COLORECTAL CANCER. MARIA DIAZ-MECO, PH.D. AND JORGE MOSCAT, PH.D., LED RESEARCH THAT REVEALED TWO GENETIC MARKERS THAT CLEARLY IDENTIFY THE SERRATED SUBGROUP OF COLORECTAL CANCER TUMORS. THE STUDY, PERFORMED IN MICE, ALSO IDENTIFIED TWO DRUGS THAT WERE SUCCESSFUL IN REDUCING THE NUMBER AND SIZE OF THESE TUMORS. THE FINDINGS SUGGEST A POTENTIAL BIOMARKER AND PROMISING TREATMENT APPROACH FOR THIS OFTEN-DEADLY CANCER. DISORDERS OF METABOLISM RESEARCH TO RESTORE INSULIN PRODUCTION IN DIABETES. IF YOU HAVE DIABETES, THERE IS A STRONG CHANCE YOU ARE EITHER ON INSULIN THERAPY NOW OR WILL BE IN THE FUTURE. A NEW STUDY BY FRED LEVINE, M.D., PH.D., FOUND THAT UNDER THE RIGHT CIRCUMSTANCES, INSULIN-MAKING "BETA" CELLS COULD BE REGENERATED IN MICE USING THREE DRUGS. ALTHOUGH MORE RESEARCH IS NEEDED, THE FINDINGS COULD ONE DAY FREE MILLIONS OF PATIENTS FROM DAILY DOSES OF INSULIN. MANNOSE'S UNEXPECTED EFFECTS ON THE MICROBIOME AND WEIGHT GAIN. HUDSON FREEZE, PH.D., PUBLISHED RESEARCH DESCRIBING HOW MICE FED A FATTY DIET AND MANNOSE (A SUGAR) WERE PROTECTED FROM WEIGHT GAIN AND WERE MORE FIT. THE EFFECTS WERE ATTRIBUTED TO CHANGES IN THE GUT MICROBIOME BUT WERE ONLY ATTAINED WHEN THE MICE RECEIVING MANNOSE WERE YOUNG, SUGGESTING THE GUT MICROBIOME IS VERY DYNAMIC EARLY IN LIFE. THE RESEARCH CONFIRMS THE IMPORTANT ROLE OF THE GUT MICROBIOME IN METABOLISM AND MAY LEAD TO NEW THERAPIES FOR TREATING OBESITY. |
| IMMUNITY | HARNESSING NANOPARTICLES TO FIGHT DRUG-RESISTANT INFECTIONS. ERKKI RUOSLAHTI, M.D., PH.D., CO-AUTHORED A STUDY THAT DESCRIBES THE FIRST EXAMPLE OF AN EFFECTIVE GENE THERAPY APPROACH TO FIGHT LETHAL BACTERIAL INFECTIONS. THE METHOD USES NANOPARTICLES TO TARGET SPECIFIC IMMUNE CELLS TO BOLSTER THE IMMUNE SYSTEM. THE TECHNIQUE WAS SUCCESSFULLY USED AGAINST A LETHAL BACTERIAL INFECTION OF STAPHYLOCOCCUS AUREUS PNEUMONIA IN MICE. NEW INSIGHTS INTO T CELL SURVIVAL. A HEALTHY POOL OF CIRCULATING T CELLS IS ESSENTIAL TO KILL PATHOGENS, MAKE ANTIBODIES, SHUT DOWN THE IMMUNE SYSTEM TO PREVENT UNCONTROLLED INFLAMMATION AND AUTOIMMUNE DISORDERS-AND EVEN FIGHT CANCER. A NEW STUDY BY MAXIMILIANO D'ANGELO, PH.D., IDENTIFIED A NUCLEAR PORE PROTEIN THAT IS CRITICAL FOR THE SURVIVAL OF CIRCULATING T CELLS, PAVING THE WAY FOR POTENTIAL ADVANCES IN IMMUNOTHERAPY. GUT MICROBIOME DIRECTS THE IMMUNE SYSTEM TO FIGHT CANCER. IMMUNOTHERAPY HAS BEEN A SIGNIFICANT BREAKTHROUGH IN CANCER TREATMENT-BUT IT DOESN'T WORK FOR EVERYONE. ZE'EV RONAI, PH.D., LED A WORLDWIDE COLLABORATION DEMONSTRATING A CAUSAL LINK BETWEEN THE GUT MICROBIOME AND THE IMMUNE SYSTEM'S ABILITY TO FIGHT CANCER. THE STUDY IDENTIFIED A COCKTAIL OF 11 BACTERIAL STRAINS THAT ACTIVATE THE IMMUNE SYSTEM AND SLOW THE GROWTH OF MELANOMA IN MICE. THE FINDINGS OPEN NEW RESEARCH AVENUES TO TURN ON ANTI-TUMOR IMMUNITY IN PATIENTS WITH CANCER. PATH TO DEADLY SEPSIS VARIES BY BACTERIAL INFECTION. SEPSIS IS A POTENTIALLY DEADLY CONDITION THAT OCCURS WHEN THE BODY REACTS TO AN INFECTION IN THE BLOODSTREAM. JAMEY MARTH, PH.D., LED RESEARCH SHOWING HOW RESPONSES DURING SEPSIS CAN VARY BASED ON THE PATHOGEN. SEPSIS CAUSED BY SALMONELLA OR E. COLI (GRAM-NEGATIVE BACTERIA) ACTIVATED THE HOST INFLAMMATORY RESPONSE, REDUCING THE LIKELIHOOD OF SURVIVAL. THE FINDINGS SUGGEST THAT BOOSTING ANTI-INFLAMMATORY ENZYMES MAY BE A FIRST-LINE THERAPEUTIC DEFENSE AGAINST THESE TYPES OF INFECTIONS. NEUROSCIENCE ANTIMICROBIAL PROTEIN IMPLICATED IN PARKINSON'S DISEASE. WANDA REYNOLDS, PH.D., MADE A DISCOVERY SHOWING THAT AN IMMUNE SYSTEM PROTEIN THAT USUALLY PROTECTS OUR BODIES FROM PATHOGENS IS ABNORMALLY PRODUCED DURING PARKINSON'S DISEASE. THE DISCOVERY INDICATES THAT DEVELOPING A DRUG THAT BLOCKS THE PROTEIN, CALLED MYELOPEROXIDASE, MAY HELP PEOPLE WITH PARKINSON'S DISEASE. ALS RESEARCH REVEALS NEW AVENUE FOR THERAPEUTICS DISCOVERY. AMYOTROPHIC LATERAL SCLEROSIS (ALS, OFTEN REFERRED TO AS LOU GEHRIG'S DISEASE) IS CAUSED BY LOSS OF MOTOR NEURONS IN THE BRAIN AND SPINAL CORD, WHICH LEADS TO GRADUAL MUSCLE DECLINE. HUAXI XU, PH.D., REVEALED THAT A PROTEIN CALLED MEMBRALIN PLAYS A KEY ROLE IN ALS AND IDENTIFIED A MEMBRALIN-BOOSTING GENE THERAPY THAT EXTENDED THE LIFE OF MICE WITH ALS-LIKE SYMPTOMS. ADDITIONAL RESEARCH AND CLINICAL TRIALS MAY ADVANCE THE APPROACH TO TREAT PATIENTS WITH THE DISEASE. MUSCLE DISCOVERY MAY OPEN NEW TREATMENT PATHS FOR ALS. LORENZO PURI, M.D., LED RESEARCH SHOWING HOW THE CELLS NEEDED TO HEAL OUR MUSCLES-CALLED FIBRO-ADIPOGENIC PROGENITORS (FAPS)-HAVE A DARK SIDE. IN NEURODEGENERATIVE DISEASES, SUCH AS ALS (LOU GEHRIG'S DISEASE), FAPS SIGNAL THE IMMUNE SYSTEM TO GO INTO OVERDRIVE, CAUSING MUSCLE WASTING AND SCARRING. BLOCKING FAP'S SIGNAL IN MOUSE MODELS OF ALS STOPPED MUSCLE WASTING AND SCARRING, SUGGESTING A NEW APPROACH TO TREAT THE DISEASE. DNA RECOMBINATION IN THE BRAIN LINKED TO ALZHEIMER'S DISEASE. JEROLD CHUN, M.D., PH.D., PUBLISHED BREAKTHROUGH RESEARCH DESCRIBING HOW GENE RECOMBINATION TAKES PLACE IN NORMAL BRAINS-BUT GOES AWRY IN ALZHEIMER'S DISEASE. GENE RECOMBINATION REQUIRES AN ENZYME CALLED REVERSE TRANSCRIPTASE, THE SAME TYPE OF ENZYME USED BY THE HIV VIRUS TO INFECT CELLS. THE FINDINGS PROVIDE SCIENTIFIC RATIONALE FOR CLINICALLY TESTING THE ANTIRETROVIRAL DRUGS THAT HAVE BEEN USED SAFELY FOR YEARS IN HIV PATIENTS AS AN ALZHEIMER'S THERAPY. CHILDREN'S HEALTH BOOSTING MUSCLE STEM CELLS TO TREAT MUSCULAR DYSTROPHY. LYING WITHIN OUR MUSCLES ARE STEM CELLS, INVISIBLE ENGINES THAT DRIVE THE TISSUE'S GROWTH AND REPAIR. ALESSANDRA SACCO, PH.D., UNCOVERED SPECIFIC CELL PROTEINS THAT REGULATE HOW MUSCLE STEM CELLS DECIDE WHETHER TO SELF-RENEW OR DIFFERENTIATE-AN INSIGHT THAT COULD LEAD TO MUSCLE-BOOSTING THERAPEUTICS FOR MUSCULAR DYSTROPHIES OR AGE-RELATED MUSCLE DECLINE. TRANSLATIONAL MEDICINE NEW STRATEGIC INITIATIVE WITH WARF THERAPEUTICS. THE INSTITUTE FORMALIZED A RESEARCH COLLABORATION AGREEMENT WITH WARF THERAPEUTICS-A PROGRAM OF THE WISCONSIN ALUMNI RESEARCH FOUNDATION ESTABLISHED IN 2018 TO TRANSLATE PROMISING BIOMEDICAL DISCOVERIES FROM THE UNIVERSITY OF WISCONSIN-MADISON INTO NOVEL MEDICINES. UNDER THE TERMS OF THE 5-YEAR AGREEMENT, WARF AND UW SCIENTISTS WILL WORK WITH THE PREBYS CENTER TO TRANSITION CLINICALLY RELEVANT TARGETS TO EARLY-STAGE DRUG DISCOVERY PROJECTS. ELI LILLY COLLABORATION ADVANCES TO PHASE 1 CLINICAL TRIAL. THE FIRST HEALTHY SUBJECT WAS DOSED IN A PHASE 1 CLINICAL TRIAL EVALUATING LY3361237, A BIOLOGIC THAT INHIBITS INFLAMMATION BY ACTIVATING AN IMMUNE CHECKPOINT RECEPTOR. THE SBP RESEARCH TEAM, LED BY CARL WARE, PH.D., PROVIDED DEEP FOUNDATIONAL SCIENTIFIC KNOWLEDGE FOR THE COMPOUND THAT MAY BENEFIT PATIENTS WITH IMMUNOLOGICAL DISORDERS SUCH AS LUPUS, PSORIASIS AND RHEUMATOID ARTHRITIS. THE COLLABORATION WITH ELI LILLY WAS FORMED IN 2015. MAYO CLINIC DRUG DISCOVERY COLLABORATION. THE COLLABORATION BETWEEN SBP AND THE MAYO CLINIC CONTINUES TO ADVANCE PROJECTS AIMED AT SPEEDING THE TRANSLATION OF SCIENTIFIC DISCOVERIES INTO POTENTIAL NEW DRUGS. BOTH INSTITUTIONS HAVE COLLABORATED ON MORE THAN 65 PROJECTS THAT HAVE GARNERED MORE THAN $11.3M IN GRANT FUNDING FROM NIH. THE COLLABORATION'S JOINT STEERING COMMITTEE LAST MET IN DECEMBER 2018 AND SELECTED THREE NEW PROJECTS - FOCUSED ON ALZHEIMER'S DISEASE, BREAST CANCER AND POLYCYSTIC KIDNEY DISEASE - TO ADD TO ITS GROWING PORTFOLIO. MAYO CLINIC INVESTIGATORS WILL PARTNER WITH THE PREBYS CENTER TO JOINTLY DEVELOP PRELIMINARY DATA PACKAGES SUITABLE FOR COMPETITIVE NIH DRUG DISCOVERY GRANT APPLICATIONS. SAN DIEGO ALZHEIMER'S COLLABORATION4CURE (C4C) INITIATIVE. ALZHEIMER'S SAN DIEGO, MRS. DARLENE SHILEY, COUNTY SUPERVISOR DIANE JACOB AND MAYOR KEVIN FAULCONER ALL REAFFIRMED THEIR COMMITMENT TO THE C4C INITIATIVE (TO FUND LOCAL ALZHEIMER'S DRUG DISCOVERY RESEARCH) BY PLEDGING ADDITIONAL FUNDING FOR A 4TH ROUND OF PROPOSALS. SBP'S PREBYS CENTER HAS BEEN INVOLVED SINCE ITS INCEPTION AND HAS BEEN PROUD TO SERVE AS THE DESIGNATED DRUG DISCOVERY CENTER FOR AWARDED PROPOSALS. IN OCTOBER 2018, THE PREBYS CENTER TEAM SHARED THAT THEY HAVE IDENTIFIED AN INHIBITOR THAT BINDS TO A MUTANT FORM OF THE PROTEIN TREM-2. TREM-2 IS THOUGHT TO PLAY A PROTECTIVE ROLE AGAINST ALZHEIMER'S DISEASE AND MUTATIONS IN TREM-2 INCREASE THE RISK OF ALZHEIMER'S DISEASE. THIS RESEARCH IS FUNDED BY A $1.3M GRANT FROM NIH. ELIMINATING HIV ONCE AND FOR ALL. ANTIRETROVIRAL THERAPIES HAVE MADE IT POSSIBLE FOR PEOPLE TO LIVE WITH HIV FOR DECADES. HOWEVER, SMALL RESERVOIRS OF HIV LIVE IN CELLS, LYING DORMANT AND GOING UNDETECTED BY THE IMMUNE SYSTEM. IF RETROVIRAL THERAPY IS DISCONTINUED, THE VIRUS REAWAKENS TO PRODUCE MORE VIRUSES AND INFECT CELLS. WITH SUPPORT FROM THE INSTITUTE'S TRANSLATIONAL SCIENCE INITIATIVE, THE LABORATORY OF SUMIT CHANDA, PH.D. WILL BE WORKING TO ADVANCE A COMPOUND DESIGNED TO REACTIVATE LATENT HIV-INFECTED CELLS SO THEY CAN BE KILLED OFF ONCE AND FOR ALL-A "SHOCK AND KILL" STRATEGY. FUNDING WILL SUPPORT STUDIES OF THE COMPOUND IN AN IN VIVO NON-HUMAN PRIMATE MODEL OF HIV LATENCY. SBP TECHNOLOGY ADVANCES TO PHASE 1 CLINICAL TRIAL. ANTI-CANCER TECHNOLOGY DEVELOPED IN THE LAB OF ERKKI RUOSLAHTI, M.D., PH.D., ADVANCED TO A PHASE 1 CLINICAL TRIAL FOR PANCREATIC CANCER. THE TECHNOLOGY HAS BEEN USED TO CREATE CEND-1, A COMPOUND DESIGNED TO IMPROVE THE EFFICACY OF ANTI-CANCER DRUGS. CEND-1 IS CO-ADMINISTERED WITH ANTI-CANCER DRUGS TO ENHANCE THEIR TUMOR PENETRATION, THEREBY IMPROVING EFFICACY OF THE THERAPY AND MINIMIZING TOXICITY. CEND-1 IS EXCLUSIVELY LICENSED TO DRUGCENDR, INC. COLLABORATING WITH USC. SBP'S PREBYS CENTER FINALIZED A RESEARCH COLLABORATION AGREEMENT WITH DR. JOHN CARPTEN OF USC. THE WORK FOCUSES ON COMPLETING A HIGH-THROUGHPUT SCREEN OF SBP'S CHEMICAL LIBRARIES IN SEARCH OF PROTOTYPE CHEMICALS, WHICH COULD BE DEVELOPED INTO TREATMENTS FOR BREAST CANCER. PROGRESS TOWARD NEW CANCER THERAPEUTICS. SBP'S PREBYS CENTER PRESENTED AT THE NCI CHEMICAL BIOLOGY CONSORTIUM (CBC) STEERING COMMITTEE MEETING TO REPORT ON THE RAPID PROGRESS OF TWO SBP-ORIGINATED PROJECTS ON EMERGENT CANCER TARGETS. THE PROJECTS, LED BY JORGE MOSCAT, PH.D. AND MARIA DIAZ-MECO, PH.D., AND NICHOLAS COSFORD, PH.D. AND LUTZ TAUTZ, PH.D., HAVE SO FAR GARNERED $2.5M IN FUNDING FROM CBC. BOTH PROJECTS EMPLOY KEY HIGH-THROUGHPUT SCREENING TECHNOLOGY THAT THE PREBYS CENTER HAS PARTICULAR EXPERTISE WITH AND THAT ENABLED THE IDENTIFICATION OF NOVEL COMPOUNDS WITH DISTINCT IMPROVEMENTS OVER CURRENT COMPETITOR COMPOUNDS. |
| FORM 990, PART VI, LINE 11B | PROCESS USED BY MANAGEMENT AND/OR GOVERNING BODY TO REVIEW FORM 990 THE 990 IS PREPARED BY THE FINANCE DEPARTMENT. IT IS REVIEWED BY THE INSTITUTE'S TAX ADVISORS, SELECTED MEMBERS OF MANAGEMENT INCLUDING THE CFO AND AUDIT COMMITTEE AND PROVIDED TO MEMBERS OF THE BOARD PRIOR TO FILING. |
| FORM 990, PART VI, LINE 12C | DESCR OF PROCESS TO MONITOR TRANSACTIONS FOR CONFLICT OF INTEREST CONFLICT OF INTEREST STATEMENTS ARE GIVEN TO MANAGEMENT STAFF AND PRINCIPAL INVESTIGATORS ON A PERIODIC BASIS TO REPORT ON CONFLICTS OR LACK OF CONFLICTS. THE STATEMENTS ARE REVIEWED ANNUALLY BY THE SENIOR DIRECTOR, INTELLECTUAL PROPERTY AND THE SENIOR DIRECTOR, SPONSORED RESEARCH, WITH A SUMMARY OF THE REVIEW PROVIDED TO THE CFO. AN ASSESSMENT IS MADE AS TO WHETHER A CONFLICT CAN BE MANAGED BY THE EXISTING DEPARTMENTS AND PRACTICES. CONFLICTS ARE BROUGHT TO THE BOARD OF TRUSTEES ON AN AS NEEDED BASIS. CONFLICTS AND POTENTIAL CONFLICTS THAT INVOLVE THE CEO OR THE PRESIDENT ARE BROUGHT TO THE BOARD OF TRUSTEES TO ADDRESS ANY ACTUAL OR POTENTIAL POSSIBILITY THAT THE DESIGNATED REVIEWERS (I.E., SENIOR DIRECTOR, INTELLECTUAL PROPERTY AND THE SENIOR DIRECTOR, SPONSORED RESEARCH, AND THE CFO) COULD BE PRESSURED TO MAKE BIASED DECISIONS IN MANAGING CONFLICTS INVOLVING THE CEO OR PRESIDENT. AS TO RESTRICTIONS IMPOSED: THE INSTITUTE WILL EMPLOY THE MECHANISM THAT IS THE BEST FIT WITH THE FACTS AND CIRCUMSTANCES OF ANY IDENTIFIED CONFLICT OF INTEREST. METHODS TO MANAGE POTENTIAL CONFLICTS/ENFORCEMENT MECHANISM: REVIEWING MANAGEMENT IS RESPONSIBLE FOR MANAGING, REDUCING, OR ELIMINATING REAL OR POTENTIAL CONFLICTS OF INTEREST. EXAMPLES OF CONDITIONS OR RESTRICTIONS THAT MIGHT BE IMPOSED TO MANAGE, REDUCE, OR ELIMINATE CONFLICTS OF INTERESTS INCLUDE: -PUBLIC DISCLOSURE OF SIGNIFICANT FINANCIAL INTERESTS -MONITORING OF RESEARCH BY INDEPENDENT REVIEWERS -MODIFICATION OF THE RESEARCH PLAN -DISQUALIFICATION FROM PARTICIPATION IN THE PORTION OF FUNDED RESEARCH THAT COULD BE AFFECTED BY SIGNIFICANT FINANCIAL INTEREST -DIVESTITURE OF SIGNIFICANT FINANCIAL INTERESTS -SEVERANCE OF RELATIONSHIPS THAT CREATE ACTUAL OR POTENTIAL CONFLICTS -REVIEW OF COMMERCIAL SPONSORED RESEARCH AGREEMENTS FOR SCIENTIFIC MERIT BY THE PROGRAM PLANNING COMMITTEE -REMOVAL OF AN AFFECTED PARTY FROM NEGOTIATION WITH A COMPANY WITH WHICH HE/SHE HAS SIGNIFICANT FINANCIAL INTEREST. |
| FORM 990, PART VI, LINES 15A & 15B | PROCESS FOR DETERMINING COMPENSATION COMPENSATION FOR THE CEO, THE PRESIDENT, CHIEF FINANCIAL OFFICER, AND OTHER KEY EMPLOYEES IS ESTABLISHED ACCORDING TO INSTITUTE POLICIES WHICH ARE DESIGNED TO MEET THE IRS STANDARD FOR "REBUTTABLE PRESUMPTION OF REASONABLENESS". THE COMPENSATION COMMITTEE OF THE BOARD OF TRUSTEES, CONSISTING OF FOUR INDEPENDENT TRUSTEES, REVIEWS COMPARABILITY DATA PROVIDED BY AN INDEPENDENT EXTERNAL CONSULTANT THAT INCORPORATES AND EVALUATES INSTITUTE DATA AND THAT OF COMPARABLE ORGANIZATIONS AND MARKETS FROM WHICH THE INSTITUTE DRAWS ITS EXECUTIVE TALENT. UTILIZING THIS INFORMATION, THE COMPENSATION COMMITTEE, WHICH TYPICALLY SEEKS TO ESTABLISH COMPENSATION BETWEEN THE 50TH AND THE 75TH PERCENTILE OF THE COMPARABILITY DATA, MAKES A DETERMINATION WHETHER THE PROPOSED COMPENSATION IS REASONABLE. THE COMPENSATION COMMITTEE HAS BEEN DELEGATED AUTHORITY BY THE BOARD OF TRUSTEES TO REVIEW AND APPROVE COMPENSATION OF ALL POSITIONS EXCEPT FOR THE CEO. THE CEOS COMPENSATION PACKAGE IS REVIEWED AND APPROVED INITIALLY BY THE COMPENSATION COMMITTEE AND THEN GOES TO THE EXECUTIVE COMMITTEE FOR FINAL APPROVAL. THE COMPENSATION COMMITTEE CONTEMPORANEOUSLY AND ADEQUATELY DOCUMENTS THE BASIS FOR ITS DETERMINATION AND RECOMMENDATION TO THE EXECUTIVE COMMITTEE. IF APPROVED BY THE EXECUTIVE COMMITTEE, THE CEO COMPENSATION PACKAGE IS THEN IMPLEMENTED AND SUCH DOCUMENTATION IS KEPT IN THE WRITTEN AND ELECTRONIC RECORDS OF THE BOARD OF TRUSTEES. THE PROCESS WAS LAST COMPLETED ON JUNE 6, 2018 FOR THE FOLLOWING POSITIONS: 1) PRESIDENT 2) CFO 3) VP BUSINESS DEVELOPMENT 4) VP PHILANTHROPY 5) SVP DRUG DISCOVERY & DEVELOPMENT 6) CANCER CENTER DIRECTOR/PROFESSOR 7) INFECTIOUS & INFLAMMATORY DISEASE CENTER DIRECTOR/PROFESSOR |
| FORM 990, PART VI, LINE 19 | PROCESS FOR MAKING DOCUMENTS AVAILABLE TO THE PUBLIC DOCUMENTS ARE AVAILABLE UPON REQUEST. |
| Software ID: | |
| Software Version: |